000227908 001__ 227908
000227908 005__ 20190615090449.0
000227908 013__ $$d20170119$$bUS$$cA1$$aUS2017014372
000227908 013__ $$d20170118$$bEP$$cA2$$aEP3116485
000227908 013__ $$d20160121$$bWO$$cA3$$aWO2015136061
000227908 013__ $$d20150917$$bWO$$cA2$$aWO2015136061
000227908 02470 $$2EPO Family ID$$a52875103
000227908 02470 $$2TTO$$a6.1380
000227908 037__ $$aPATENT
000227908 245__ $$aDrug Combination for Treatment of Proliferative Diseases
000227908 260__ $$c2017
000227908 269__ $$a2017
000227908 336__ $$aPatents
000227908 520__ $$aAngiogenesis inhibitory drug combination obtained according to a specific algorithm, preferably a FSC, in which an initial combination of drugs is iteratively adjusted. The drug combination according to the invention may advantageously comprise a RAPTA-C compound. In a more specific case the combination comprises RAPTA-C and eriotinib.
000227908 700__ $$g168504$$0245027$$aNowak-sliwinska, Patrycja
000227908 700__ $$aDyson, Paul
000227908 700__ $$aGriffioen, Arjan
000227908 700__ $$aWeiss, Andrea
000227908 700__ $$aVan Den Bergh, Hubert
000227908 700__ $$aDing, Xianting
000227908 909C0 $$xU10095$$0252439$$pISIC
000227908 909CO $$pSB$$ooai:infoscience.tind.io:227908
000227908 917Z8 $$x135992
000227908 937__ $$aEPFL-PATENT-227908
000227908 973__ $$aEPFL
000227908 980__ $$aPATENT